In September 2026, a team led by S. Susan Hedayati at Stony Brook University published updated clinical guidelines in the Annals of Internal Medicine, offering physicians a more nuanced framework for treating anemia in chronic kidney disease — a condition that quietly diminishes the lives of millions whose kidneys can no longer sustain the body's most fundamental rhythms. The guidelines do not claim to have solved the problem, but rather to have mapped the current boundaries of knowledge, offering eight evidence-graded recommendations alongside 49 expert consensus points that acknowledge how o
Updated Clinical Guidelines Address Anemia Management in Chronic Kidney Disease
Important knowledge gaps remain to address anemia management in CKD
Mark
Why does it matter that these guidelines came out now? Anemia in kidney disease isn't new.
Mimi
The evidence base has shifted. New drugs have come on the market, and older studies didn't compare all the options we have now. This guideline is trying to catch up to what we can actually do.
Luke
But how much of this is based on solid evidence versus expert opinion? The piece mentions 49 practice points that are just consensus—that's a lot of territory where we're not sure.
Mimi
That's fair. The eight core recommendations are graded, meaning they went through a formal evidence review. The 49 points are honest about the limits—they say "we don't have robust evidence here, but here's what experienced clinicians think."
Mark
So a doctor reading this knows which parts are backed by trials and which parts are educated guesses?
Mimi
Exactly. And the authors are explicit that they need more research—large trials in different populations, different settings. They're not claiming this is final.
Luke
The hemoglobin target of below 11.5 g/dL—is that new, or has that been the standard?
Mimi
The guideline emphasizes individualization, which is the shift. It's not "always aim for this number." It's "consider the patient, then decide."
Mark
And for the patient on hemodialysis, the preference for IV iron over oral—that's a practical change?
Mimi
Yes. It's more direct, more reliable. You're not relying on the gut to absorb it.
Luke
But we should note: this is one guideline. Other organizations might have different recommendations. And the authors themselves say the evidence gaps are significant.
Mimi
True. This is a snapshot of current best thinking, not a final answer.
Il Polso
- Millions of chronic kidney disease patients face anemia because failing kidneys can no longer signal the body to produce adequate red blood cells — a silent cascade with serious consequences.
- The new guidelines push back against one-size-fits-all treatment, insisting that hemoglobin targets be individualized based on each patient's age, symptoms, values, and overall health profile.
- For hemodialysis patients specifically, intravenous iron is now preferred over oral supplements, with precise blood markers guiding when to start and stop therapy.
- Erythropoiesis-stimulating agents remain the first-line medication of choice over newer HIF-PHI drugs, with maintenance hemoglobin kept below 11.5 g/dL to balance benefit against potential harm.
- The authors openly acknowledge that 49 of their guidance points rest on expert consensus rather than strong evidence, and call for large, diverse randomized trials to close the remaining knowledge gaps.
In September 2026, a team led by S. Susan Hedayati at Stony Brook University published updated clinical guidelines in the Annals of Internal Medicine, offering physicians a more nuanced framework for treating anemia in chronic kidney disease — a condition that quietly diminishes the lives of millions whose kidneys can no longer sustain the body's most fundamental rhythms. The guidelines do not claim to have solved the problem, but rather to have mapped the current boundaries of knowledge, offering eight evidence-graded recommendations alongside 49 expert consensus points that acknowledge how often medicine must act in the space between certainty and the unknown.
On September 15, 2026, a new clinical guideline appeared in the Annals of Internal Medicine addressing one of the quieter crises in nephrology: anemia in chronic kidney disease. Led by S. Susan Hedayati and colleagues at Stony Brook University School of Medicine, the team spent months reviewing the scientific literature, grading the strength of evidence behind each recommendation, and building a framework designed to reflect what medicine actually knows — and where it does not yet have answers.
The resulting guideline centers on eight core recommendations. For patients on hemodialysis, intravenous iron is preferred over oral supplements, with specific blood markers — transferrin saturation and ferritin levels — guiding when to begin and when to stop. Before prescribing any medication, physicians are urged to first identify and correct underlying causes of anemia: bleeding, nutritional deficiencies, infections, or other treatable conditions that may be suppressing blood counts independently.
When medication becomes necessary, erythropoiesis-stimulating agents are recommended as the first choice over the newer class of hypoxia-inducible factor-prolyl hydroxylase inhibitors. Crucially, the guideline resists uniform hemoglobin targets, calling instead for individualized thresholds that account for each patient's age, symptoms, values, and overall condition. Once treatment is underway, hemoglobin should be maintained below 11.5 grams per deciliter — a threshold calibrated to balance therapeutic benefit against known risks.
Beyond these eight graded recommendations lies a broader structure of 49 practice points drawn from expert consensus, covering the many clinical questions where the research base remains too thin for formal systematic review. The authors were candid about what remains unresolved, calling for large, rigorous randomized controlled trials across diverse populations and healthcare settings. The guideline presents itself not as a destination, but as an honest accounting of where medicine stands — and a clear signal of where it still needs to go.
On September 15th, a new clinical guideline landed in the Annals of Internal Medicine with instructions for how doctors should manage anemia in patients with chronic kidney disease—a condition affecting millions of people whose kidneys can no longer produce enough of the hormone that signals the body to make red blood cells.
The guideline came from S. Susan Hedayati and colleagues at Stony Brook University School of Medicine, who spent months reviewing the scientific literature on anemia treatment in CKD, grading the strength of evidence behind each recommendation. What emerged was a framework built on eight core recommendations, each one reflecting what the evidence actually supports—and where it falls short.
The practical details matter. For patients on hemodialysis, the guideline recommends intravenous iron rather than oral supplements, using specific blood markers—transferrin saturation and ferritin levels—to decide when iron therapy is needed and when to stop. Before reaching for medications that stimulate red blood cell production, doctors should first hunt for and fix correctable causes of anemia: bleeding, nutritional deficiencies, infections, or other treatable problems that might be dragging down the blood count on their own.
When medication is necessary, the guideline favors erythropoiesis-stimulating agents, or ESAs, as the first choice over a newer class called hypoxia-inducible factor-prolyl hydroxylase inhibitors, or HIF-PHIs. But the guideline resists a one-size-fits-all approach to hemoglobin targets. Instead, it calls for individualized thresholds—meaning doctors should consider each patient's age, symptoms, values, and overall health when deciding what hemoglobin level to aim for. Once treatment begins, the guideline recommends keeping hemoglobin below 11.5 grams per deciliter during maintenance therapy, a threshold designed to balance the benefits of treatment against potential harms.
Beyond these eight graded recommendations sits a larger structure: 49 practice points representing expert consensus on questions where the research base was too thin or fragmented for a formal systematic review. These points acknowledge the reality of clinical medicine—that doctors often must make decisions in the absence of perfect evidence, guided by experience and judgment.
The authors were candid about what remains unknown. "Important knowledge gaps remain to address the management of anemia in people with CKD," they wrote, noting that closing those gaps will require large, rigorous randomized controlled trials conducted across different healthcare settings and in diverse patient populations. The guideline is not an endpoint but a waypoint—a summary of what we know now, with a clear map of what still needs investigation.
Citazioni salienti
Important knowledge gaps remain to address the management of anemia in people with CKD. Addressing these gaps will require large, well-designed randomized controlled trials and pragmatic trials across diverse settings and target populations.— S. Susan Hedayati and colleagues, Stony Brook University School of Medicine
Vuoi la storia completa?
Leggi l'originale su Medical Xpress ↗
Health & Medicine